General Inclusion Criteria  Male or female age ≥18 yrs Carcinoid Heart Disease NYHA Class II - IV Severe symptomatic tricuspid regurgitation Inoperable due to active tumour process or patient declines an operative intervention Patient willing and able to consent and comply with specified study evaluations Adequate understanding of written or spoken English (to complete validated questionnaires)  General Exclusion Criteria  Previous tricuspid valve repair or replacement Permanent vena cava filter Mega atrium Tricuspid valve stenosis Thrombosis of lower venous system Severe uncontrolled hypertension (Systolic BP ≥ 180 mmHg and/or Diastolic BP ≥ 110 mm Hg) Active endocarditis Subject is on chronic dialysis Bleeding disorders or hypercoaguable state Hemodynamic instability or on IV inotropes Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically eg contrast Contraindication to anticoagulants or antiplatelet medication Known allergy to Nitinol (Titanium or Nickel) alloy, gold or porcine tissue Untreated clinically significant coronary artery disease requiring revascularization Any Percutaneous Coronary Intervention (PCI) or transcatheter valvular intervention within 30 days prior to the index procedure or planned 3 months post the index procedure Myocardial Infarction (MI) or known unstable angina within the 30 days prior to the index procedure Pregnant or lactating; or female of childbearing potential with a positive pregnancy test 24 hours before any study-related radiation exposure Contraindication to long-term anticoagulation Life expectancy according to tumour development is less than 12 months Impaired judgment and/or is undergoing emergency treatment